home
sitemap
print
recommend

2009 Portfolio News


News from the portfolios of HBM BioVentures and HBM BioCapital

7.12.2009 ChemoCentryx's Traficet-EN demonstrates effectiveness in Crohn's disease
23.11.2009 Nereus Pharmaceuticals presents positive study of randomized phase 2
clinical trial of Plinabulin (NPI-2358) in non-small cell lung cancer
5.11.2009 Biovitrum - The creation of a new niche specialty pharmaceutical company
focused on rare diseases - with strong cash flow generation and growth
potential
2.11.2009 Probiodrug closes series B financing round exceeding Euro 36 million
(USD 54 million)
28.10.2009 Asthmatx receives FDA advisory panel recommendation for 'approvable with
conditions' for bronchial thermoplasty with the Alair system for severe Asthma
28.10.2009 Nabriva Therapeutics raises Euro 15 million (USD 22 million)
26.10.2009 PTC Therapeutics initiates phase 2 clinical trial of Ataluren (PTC124) in
patients with Hemophilia
26.10.2009 Lux Biosciences's potential of LUVENIQ (LX211) as first disease modifying
treatment for sight-threatening non-infectious Uveitis highlighted at American
Academy of Ophthalmology
19.10.2009 Lux Biosciences completes $50 million series B financing
8.10.2009 Paratek Pharmaceuticals signs worldwide license and commercialization
agreement for PTK 0796, broad-spectrum oral and IV antibiotic in phase 3
5.10.2009 mtm laboratories extends series C financing round by EUR 7 million bringing
total to EUR 39 million (USD 57 million)
25.9.2009 Sloning closes growth financing round led by LBBW Venture
23.9.2009 Lux Biosciences reports phase 1 safety results and open label efficacy
results for LX214, a potential best-in-class treament for Dry Eye
14.9.2009 HBM Partners' successful trade sale of Swiss biotech company ESBATech
to Alcon
10.9.2009 Mpex Pharmaceuticals announces positive phase 2b clinical trial results
with Aeroquin (MP-376) treatment in Cystic Fibrosis patients
10.9.2009 PTC Therapeutics initiates registration-directed Phase 3 trial of Ataluren
in Cystic Fibrosis
4.9.2009 MiCardia announces completion of enrollment in "DYANA" European
CE study
3.9.2009 Successful sale of BRAHMS in an all-cash transaction to Thermo Fisher
Scientific: Net profit for HBM advised antities of EUR 134.2 million, or
21.6 times the invested equity
10.8.2009 PTC Therapeutics announces achievement of major milestone in Schering-
Plough Hepatitis C collaboration
7.7.2009 Zosana Pharma, Inc. secures $30 million in new round of financing
2.7.2009 Brahms - New cardiac marker copeptin accelerates diagnosis of acute
myocardial infarction (AMI)